Please login to the form below

Not currently logged in


This page shows the latest BIO news and features for those working in and with pharma, biotech and healthcare.

EMA to review Bluebird’s blood disorder gene therapy

EMA to review Bluebird’s blood disorder gene therapy

Bluebird Bio announced late last week that the European Medicines Agency has accepted its gene therapy LentiGlobin for accelerated review. ... medical officer, Bluebird Bio.

Latest news

More from news
Approximately 12 fully matching, plus 183 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Bluebird Bio: on the cusp of a gene therapy revolution. Nick Leschly talks to PME about Bluebird's remarkable gene therapy pipeline and why it’s filing first in Europe. ... The next company to play its hand in this biotech-led transformation of

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    Van den Hoven wants SPCs to hold firm in Europe but with a waiver for generic and bio-similar companies to compete with India, Canada and China - not restricted by SPCs -

  • Deal Watch December 2016 Deal Watch December 2016

    Defymed. Not disclosed. Not disclosed. Bio-artificial pancreas for Type 1 diabetes.

  • Deal Watch October 2016 Deal Watch October 2016

    Another example is DM Bio, a joint venture between Dong A of South Korea and Meiji Seika of Japan who this month signed a deal with Gedeon Richter for a biosimilar

  • Deal Watch September 2016 Deal Watch September 2016

    bio has paid an upfront fee of $15m, milestone payments of $1+ bn plus royalties and R&D funding. ... 1, 695. Medigene /Bluebird bio. Licence. Development and commercialisation of T cell receptor (TCR) immunotherapies against four targets, P1 ready,

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Random42 exhibiting at BIO-Europe 2018

    Random42 exhibiting at BIO-Europe 2018. Random42 will be attending BioEurope in Copenhagen from November 5th – 7th. ... For more information about BIO-Europe please visit their website:

  • A4P Bio Consulting Ltd

    A4P Bio Consulting Ltd. As experts in biomarkers, bioanalysis, pharmacokinetics, logistics and quality systems management A4P deliver scientifically robust, regulatory compliant, cost effective and value added solutions for the global life

  • emotive. expands client services team

    Alongside his role at emotive. Rob is currently studying for an MSc in Bio-business at Birkbeck, University of London, with a focus on entrepreneurship in the bio-industry.

  • The Biosimilar Challenge

    The Biosimilar Challenge. The ‘ biosimilar challenge’ (or ‘ bio battle’) is one of the most significant commercial changes we have seen in the pharma industry.

  • Cello Health BioConsulting Appoints Senior Pharma Marketer As President

    He will drive our expansion, not only working with our growing team of strong consultants as leading advisers to the bio-pharmaceutical and healthcare sector, but also contributing to our overarching

More from PMHub
Approximately 2 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...